Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126130282 | 12613028 | 2 | F | 20160725 | 20160802 | 20160805 | EXP | US-ALVOGEN-2016-ALVOGEN-026826 | ALVOGEN | SAIFEE NH, RANJITKAR P, GREENE DN, BAIRD GS. SPECTRAL WAVELENGTH AND PH: A MECHANISM FOR NAPROXEN METABOLITE POSITIVE INTERFERENCE IN TOTAL BILIRUBIN ASSAYS. AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2015;143(1) : A021. | 57.00 | YR | F | Y | 0.00000 | 20160805 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126130282 | 12613028 | 1 | PS | NAPROXEN. | NAPROXEN | 1 | U | 20353 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126130282 | 12613028 | 1 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126130282 | 12613028 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126130282 | 12613028 | Blood bilirubin increased | |
126130282 | 12613028 | Overdose | |
126130282 | 12613028 | Suicide attempt |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |